On August 25, 2011, the FDA approved onabotulinumtoxinA (Botox®; Allergan Inc.; Irvine, California) for urinary incontinence caused by detrusor overactivity associated with neurologic conditions such as spinal cord injury or multiple sclerosis. Two clinical trials found significant decreases in weekly frequency of incontinence episodes compared with placebo. Injection of Botox into the bladder requires cystoscopy. The most common adverse effects include urinary tract infection and urinary retention.
For more information, see Botox Approved for Incontinence in Neurologic Conditions.
